Figure 7.

Coordinated dosing of TPO agonists overcomes selinexor-induced thrombocytopenia in patients. (A-B) TPO knockout mice were treated with vehicle control, selinexor (15 mg/kg every other day, for 3 doses per week), TPO (300 ng/mL, single treatment), or selinexor and TPO, and platelet counts were measured on D0 (before treatment) (A) and D6 (B). *P < .05 compared with vehicle control; n = 3 mice per group. (C-F) Representative human patient data showing the recovery effects of dosing interruption ± TPO agonists romiplostim or eltombopag on patients with selinexor-induced grade 4 thrombocytopenia. Dashed lines mark periods of selinexor and/or TPO mimetic treatment.